Table 2.

Risk ratios of overall survival and disease-free and progression-free survival in different time-points

Year	OS, DFS/PFS	RR	95% Confidence interval	P value
POC, interval CRS + NACT (n = 3)22,23,25
1-Year	OS	0.61	0.31-1.22	0.162
2-Year	OS	0.64	0.44-0.92	0.017
3-Year	OS	0.72	0.57-0.93	0.011
4-Year	OS	0.76	0.64-0.91	0.003
5-Year	OS	0.77	0.67-0.90	0.001
1-Year	DFS	0.58	0.36-0.93	0.024
2-Year	DFS	0.83	0.74-0.93	0.001
3-Year	DFS	0.89	0.82-0.96	0.005
4-Year	DFS	0.94	0.86-1.03	0.177
5-Year	DFS	0.94	0.88-1.00	0.038

POC, primary CRS (n = 2)22,27
1-Yeara	OS	0.84	0.12-5.78	0.864
2-Yeara	OS	0.84	0.32-2.24	0.735
3-Yeara	OS	0.77	0.38-1.60	0.489
4-Year	OS	0.92	0.51-1.65	0.768
5-Yeara	OS	1.14	0.69-1.88	0.599
1-Yeara	DFS	1.69	0.74-3.85	0.212
2-Yeara	DFS	1.17	0.77-1.76	0.465
3-Yeara	DFS	1.06	0.76-1.48	0.715
4-Year	DFS	0.93	0.57-1.53	0.781
5-Yeara	DFS	1.10	0.86-1.41	0.446

Recurrent OC (n = 2)24,26
1-Year	OS	0.29	0.08-1.10	0.068
2-Year	OS	1.22	0.32-4.71	0.769
3-Year	OS	0.59	0.16-2.20	0.428
4-Yearb	OS	1.50	0.87-2.60	0.147
5-Year	OS	0.85	0.45-1.62	0.626
1-Yearb	PFS	1.32	0.84-2.06	0.228
2-Yearb	PFS	1.11	0.91-1.36	0.319
3-Yearb	PFS	1.18	1.01-1.38	0.042
4-Yearb	PFS	1.18	1.01-1.38	0.042
5-Yearb	PFS	1.18	1.01-1.38	0.042

Grade ≥3 adverse events (n = 5)
	POC	1.08	0.98-1.18	0.120
	ROCb	1.20	0.57-2.51	0.629
	Overall	1.08	0.98-1.18	0.109

CRS, cytoreductive surgery; DFS, disease-free survival; NACT, neoadjuvant chemotherapy; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival; POC, primary ovarian cancer; RR, Risk ratio; ROC, recurrent ovarian cancer.

^aResults only from the subset of Lim et al.²²

^bResults only from Zivanovic et al.²⁴